Skip to content

Effect of Hesperidin on depression

Effect of Hesperidin on severity of depression, cognitive function, serum level of F2 isoprostanes, GDNF and hs-CRP in major depressive disorder

Status
Recruiting
Phases
Phase 3
Study type
Observational
Source
IRCT
Registry ID
IRCT20090901002394N41
Enrollment
48
Registered
2018-12-24
Start date
2018-08-22
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, single episode, severe with psychotic features

Interventions

Intervention 1: Control group: placebo. Intervention 2: Intervention group: hesperidin.

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Willing to participate Clinical diagnosis of major depressive disorder; A score =15 in the 17-item Hamilton Depression Rating Scale Age 18 – 65 years;Good health status based on medical history No dietary supplement use during the previous two months Not use any drugs and antidepressant Absence of benign hormone-sensitive tumors in the ovary, uterus, breast, prostate Not having thoughts about death and suicide Not having any mental illness except anxiety Do not eat citrus more than two units per day Having physical health based on history No regular use of any supplements more than twice a week, two months before the study

Exclusion criteria

Exclusion criteria: Pregnancy and lactation patient's dissatisfaction to continue cooperation Earning each non-entry criteria

Design outcomes

Secondary

MeasureTime frame
Physical activity. Timepoint: beginning and end of intervention. Method of measurement: IPAQ questionnaire.;Energy intake. Timepoint: beginning and end of intervention. Method of measurement: Three-day food record.

Primary

MeasureTime frame
Severity of depression. Timepoint: First, middle and end of intervention. Method of measurement: Hamilton Depression Scale.;Serum level of F2 Isoprostane. Timepoint: beginning and end of intervention. Method of measurement: ELIZA.;Serum level of GDNF. Timepoint: beginning and end of intervention. Method of measurement: ELIZA.;Serum level of hs-CRP. Timepoint: beginning and end of intervention. Method of measurement: ELIZA.;Cognitive function. Timepoint: beginning and end of intervention. Method of measurement: D-KEFS questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Yazdani

Iran University of Medical Sciences

r.yazdani999@yahoo.com+98 21 8670 4805

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026